Coloplast A/S (OTCMKTS:CLPBY – Get Rating) had its goal worth lowered by analysts at Barclays from 835.00 to 815.00 in a report launched on Tuesday, The Fly stories. The brokerage presently has an “underweight” score on the inventory.
Quite a few different equities analysis analysts additionally not too long ago issued stories on the inventory. Morgan Stanley began protection on shares of Coloplast A/S in a analysis report on Tuesday, October 18th. They set an “obese” score for the corporate. Jefferies Monetary Group lower Coloplast A/S from a “purchase” score to a “maintain” score in a analysis report on Tuesday, September twentieth. Credit score Suisse Group decreased their worth goal on shares of Coloplast A/S from 1,100.00 to 1,045.00 in a analysis report on Wednesday, November ninth. Lastly, UBS Group lowered their worth goal on shares of Coloplast A/S from 878.00 to 840.00 in a analysis report on Tuesday, November eighth. One analyst has rated the inventory with a promote score, three have issued a maintain score and two have issued a purchase score to the corporate. Based on MarketBeat, the corporate at present has a consensus score of “Maintain” and a median goal worth of $920.00.
Coloplast A/S Value Efficiency
Shares of CLPBY traded up $0.14 throughout buying and selling hours on Tuesday, reaching $12.31. The corporate had a buying and selling quantity of 102,912 shares, in comparison with its common quantity of 77,782. The corporate has a present ratio of 1.29, a fast ratio of 0.90 and a debt-to-equity ratio of 0.02. Coloplast A/S has a 12-month low of $9.58 and a 12-month excessive of $16.00. The agency has a 50 day easy transferring common of $11.83 and a 200-day easy transferring common of $11.43. The corporate has a market capitalization of $26.59 billion, a price-to-earnings ratio of 41.03 and a beta of 0.28.
Coloplast A/S Firm Profile
Coloplast A/S develops and sells intimate healthcare services in Denmark, the US, the UK, France, and internationally. The corporate operates by Power Care, Interventional Urology, Voice and Respiratory Care, and Wound & Pores and skin Care segments. It supplies ostomy care merchandise, together with SenSura Mio, which supplies match particular person physique shapes and optimum discretion for numerous kinds of ostomies; and SenSura Ostomy care options, in addition to ostomy equipment below the Brava model.
This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you contemplate Coloplast A/S, you will wish to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers every day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Coloplast A/S wasn’t on the record.
Whereas Coloplast A/S at present has a “Maintain” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.